Systematic analysis and validation of differential gene expression in ovarian serous adenocarcinomas and normal ovary

Journal of Cancer Research and Clinical Oncology

Volumn 139, Issue 2, 2013, Pages 347-355

  Bauerschlag, Dirk ^a   Bräutigam, Karen ^a   Moll, Roland ^b   Sehouli, Jalid ^c   Mustea, Alexander ^d   Salehin, Darius ^e   Krajewska, Maryla ^f   Reed, John C ^f   Maass, Nicolai ^a   Hampton, Garret M ^g   Meinhold Heerlein, Ivo ^a  

^a UNIVERSITY OF AACHEN MEDICAL CENTER   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY MEDICINE GREIFSWALD   (Germany)

^e Helios Hospital Krefeld   (Germany)

^f BURNHAM INSTITUTE   (United States)

^g GENENTECH INC   (United States)

Author keywords

Gene expression; Ovarian cancer; Validation

Indexed keywords

ANTIBODY; CD9 ANTIGEN; CLAUDIN 3; EPITHELIAL CELL ADHESION MOLECULE; MESOTHELIN; MUCIN 1; TUMOR MARKER;

ARTICLE; CANCER GRADING; CD24 ANTIGEN GENE; CD9 ANTIGEN GENE; CLAUDIN 3 GENE; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MESOTHELIN GENE; MICROARRAY ANALYSIS; MUCIN 1 GENE; NUCLEOTIDE SEQUENCE; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA HYBRIDIZATION; STAINING; VALIDATION STUDY; CLUSTER ANALYSIS; CYSTADENOCARCINOMA; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; OVARY; OVARY TUMOR;

CLUSTER ANALYSIS; CYSTADENOCARCINOMA, SEROUS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; OVARY;

MLCS; MLOWN;

EID: 84874996116     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-012-1334-8     Document Type: Article

References (50)

1. Auersperg N (2011) The origin of ovarian carcinomas: a unifying hypothesis. Int J Gynecol Pathol 30(1):12-21
2. Bast RC Jr (2003) Status of tumor markers in ovarian cancer screening. J Clin Oncol 21(10 Suppl):200s-205s
3. Bauerschlag DO, Ammerpohl O et al (2011) Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. Oncology 80(1-2):12-20
4. Brakora KA, Lee H et al (2004) Utility of osteopontin as a biomarker in recurrent epithelial ovarian cancer. Gynecol Oncol 93(2):361-365
5. Budiu RA, Mantia-Smaldone G et al (2011) Soluble MUC1 and serum MUC1-specific antibodies are potential prognostic biomarkers for platinum-resistant ovarian cancer. Cancer Immunol Immunother 60(7):975-984
6. Burges A, Wimberger P et al (2007) Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM × anti-CD3 antibody: a phase I/II study. Clin Cancer Res 13(13):3899-3905
7. Cristaudo A, Bonotti A et al (2011) Soluble markers for diagnosis of malignant pleural mesothelioma. Biomark Med 5(2):261-273
8. Dong Y, Walsh MD et al (1997) Expression of MUC1 and MUC2 mucins in epithelial ovarian tumours. J Pathol 183(3):311-317
9. El-Sahwi K, Bellone S et al (2010) Overexpression of EpCAM in uterine serous papillary carcinoma: implications for EpCAM-specific immunotherapy with human monoclonal antibody adecatumumab (MT201). Mol Cancer Ther 9(1):57-66
10. Fekete T, Raso E et al (2012) Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples. Int J Cancer 131(1):95-105
11. Fryer RM, Randall J et al (2002) Global analysis of gene expression: methods, interpretation, and pitfalls. Exp Nephrol 10(2):64-74
12. Hassan R, Cohen SJ et al (2010) Phase I clinical trial of the chimeric anti-mesothelin monoclonal antibody MORAb-009 in patients with mesothelin-expressing cancers. Clin Cancer Res 16(24):6132-6138
13. Havrilesky LJ, Sanders GD et al (2011) Development of an ovarian cancer screening decision model that incorporates disease heterogeneity: implications for potential mortality reduction. Cancer 117(3):545-553
14. Heinzelmann-Schwarz VA, Gardiner-Garden M et al (2004) Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10(13):4427-4436
15. Hellstrom I, Raycraft J et al (2003) The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63(13):3695-3700
16. Hennessy BT, Coleman RL et al (2009) Ovarian cancer. Lancet 374(9698):1371-1382
17. Hong S, Dong H et al (2011) Gene co-expression network and functional module analysis of ovarian cancer. Int J Comput Biol Drug Des 4(2):147-164
18. Houle CD, Ding XY et al (2002) Loss of expression and altered localization of KAI1 and CD9 protein are associated with epithelial ovarian cancer progression. Gynecol Oncol 86(1):69-78
19. Hwang JR, Jo K et al (2012) Upregulation of CD9 in ovarian cancer is related to the induction of TNF-alpha gene expression and constitutive NF-kappaB activation. Carcinogenesis 33(1):77-83
20. Jager M, Schoberth A et al (2012) Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM × anti-CD3). Cancer Res 72(1):24-32
21. Jemal A, Siegel R et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300
22. Kim JH, Herlyn D et al (2003) Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 9(13):4782-4791
23. King HC, Sinha AA (2001) Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 286(18):2280-2288
24. Konstantinopoulos PA, Spentzos D et al (2008) Gene-expression profiling in epithelial ovarian cancer. Nat Clin Pract Oncol 5(10):577-587
25. Krajewski S, Bodrug S et al (1994) Immunohistochemical analysis of Mcl-1 and Bcl-2 proteins in normal and neoplastic lymph nodes. Am J Pathol 145(3):515-525
26. Krajewski S, Krajewska M et al (1999) Prognostic significance of apoptosis regulators in breast cancer. Endocr Relat Cancer 6(1):29-40
27. Kurman RJ, Shih Ie M (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433-443
28. Kurman RJ, Shih Ie M (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer - shifting the paradigm. Hum Pathol 42(7):918-931
29. Lockhart DJ, Dong H et al (1996) Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol 14(13):1675-1680
30. Meinhold-Heerlein I, Stenner-Liewen F et al (2001) Expression and potential role of Fas-associated phosphatase-1 in ovarian cancer. Am J Pathol 158(4):1335-1344
31. Meinhold-Heerlein I, Bauerschlag D et al (2005) Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. Oncogene 24(6):1053-1065
32. Meinhold-Heerlein I, Bauerschlag D et al (2007) An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. Clin Cancer Res 13(2 Pt 1):458-466
33. Mok SC, Chao J et al (2001) Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology. J Natl Cancer Inst 93(19):1458-1464
34. Mor G, Visintin I et al (2005) Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 102(21):7677-7682
35. Ott MG, Marme F et al (2012) Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer 130(9):2195-2203
36. Ralhan R, Cao J et al (2010) EpCAM nuclear localization identifies aggressive thyroid cancer and is a marker for poor prognosis. BMC Cancer 10:331
37. Rangel LB, Agarwal R et al (2003) Tight junction proteins claudin-3 and claudin-4 are frequently over-expressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9(7):2567-2575
38. Rentrop M, Knapp B et al (1986) Aminoalkylsilane-treated glass slides as support for in situ hybridization of keratin cDNAs to frozen tissue sections under varying fixation and pretreatment conditions. Histochem J 18(5):271-276
39. Schummer M, Drescher C et al (2012) Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 125(1):65-69
40. Spellman PT, Bell D et al (2011) Integrated genomic analyses of ovarian carcinoma. Nature 474(7353):609-615
41. Spizzo G, Went P et al (2004) High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86(3):207-213
42. Spizzo G, Fong D et al (2011) EpCAM expression in primary tumour tissues and metastases: an immunohistochemical analysis. J Clin Pathol 64(5):415-420
43. Sun C, Yi T et al (2011) Efficient inhibition of ovarian cancer by short hairpin RNA targeting claudin-3. Oncol Rep 26(1):193-200
44. Taylor JM, Ankerst DP et al (2008) Validation of biomarker-based risk prediction models. Clin Cancer Res 14(19):5977-5983
45. Van Elssen CH, Frings PW et al (2010) Expression of aberrantly glycosylated Mucin-1 in ovarian cancer. Histopathology 57(4):597-606
46. Wang L, Ma J et al (2007) Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol 105(3):695-702
47. Welsh JB, Sapinoso LM et al (2001a) Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 61(16):5974-5978
48. Welsh JB, Zarrinkar PP et al (2001b) Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA 98(3):1176-1181
49. Wodicka L, Dong H et al (1997) Genome-wide expression monitoring in Saccharomyces cerevisiae. Nat Biotechnol 15(13):1359-1367
50. Yen MJ, Hsu CY et al (2006) Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 12(3 Pt 1):827-831